相似文献
1
Failure of salmeterol to inhibit circulating white cell responses and bronchoconstriction induced by platelet activating factor.
Thorax. 1992 Nov;47(11):948-51. doi: 10.1136/thx.47.11.948.
2
Inhibitory effect of UK,74505, a potent and specific oral platelet activating factor (PAF) receptor antagonist, on airway and systemic responses to inhaled PAF in humans.
Am J Respir Crit Care Med. 1994 Jul;150(1):35-40. doi: 10.1164/ajrccm.150.1.8025768.
3
Comparison of the anti-inflammatory properties of formoterol, salbutamol and salmeterol in guinea-pig skin and lung.
Br J Pharmacol. 1993 Oct;110(2):613-8. doi: 10.1111/j.1476-5381.1993.tb13855.x.
4
Salbutamol reduces pulmonary neutrophil sequestration of platelet-activating factor in humans.
Am J Respir Crit Care Med. 1996 Aug;154(2 Pt 1):529-32. doi: 10.1164/ajrccm.154.2.8756833.
5
Attenuation of platelet-activating factor induced bronchoconstriction by nedocromil sodium.
Eur Respir J. 1992 Nov;5(10):1193-6.
6
Inhibition of PAF-induced gas exchange defects by beta-adrenergic agonists in mild asthma is not due to bronchodilation.
Am J Respir Crit Care Med. 1997 Jul;156(1):17-22. doi: 10.1164/ajrccm.156.1.9610100.
7
Salbutamol inhibits pulmonary effects of platelet activating factor in man.
Am J Respir Crit Care Med. 1995 Jun;151(6):1740-4. doi: 10.1164/ajrccm.151.6.7767515.
8
Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists.
Thorax. 2001 Jul;56(7):529-35. doi: 10.1136/thorax.56.7.529.
9
Effect of beta 2-adrenoceptor agonists against platelet-activating factor-induced airway microvascular leakage and bronchoconstriction in the guinea pig.
Agents Actions. 1993 Sep;40(1-2):50-6. doi: 10.1007/BF01976751.
10
Inhibition of platelet-activating factor-induced bronchoconstriction by the leukotriene D4 receptor antagonist ICI 204,219.
Am Rev Respir Dis. 1993 Jan;147(1):215-7. doi: 10.1164/ajrccm/147.1.215.
引用本文的文献
1
[Long-acting beta(2)-adrenoceptor agonists for asthma and COPD].
Med Klin (Munich). 1997 Dec;92 Suppl 5:44-9. doi: 10.1007/BF03041980.
2
Long- versus short-acting beta 2-agonists. Implications for drug therapy.
Drugs. 1994 Feb;47(2):207-22. doi: 10.2165/00003495-199447020-00001.
本文引用的文献
1
A new method for computer-assisted determination of airways resistance.
J Appl Physiol Respir Environ Exerc Physiol. 1981 Mar;50(3):672-8. doi: 10.1152/jappl.1981.50.3.672.
2
Platelet-activating factor as a mediator of allergic disease.
J Allergy Clin Immunol. 1988 May;81(5 Pt 1):919-34. doi: 10.1016/0091-6749(88)90952-9.
3
Mechanism of platelet activating factor-induced bronchoconstriction in humans.
Am Rev Respir Dis. 1988 May;137(5):1015-9. doi: 10.1164/ajrccm/137.5.1015.
4
Risk of anaphylaxis in patients receiving beta-blocker drugs.
J Allergy Clin Immunol. 1988 Jan;81(1):1-5. doi: 10.1016/0091-6749(88)90212-6.
5
Effects of inhaled platelet activating factor on pulmonary function and bronchial responsiveness in man.
Lancet. 1986 Jul 26;2(8500):189-92. doi: 10.1016/s0140-6736(86)92489-x.
6
Effects of salbutamol on bronchoconstriction, bronchial hyperresponsiveness, and leucocyte responses induced by platelet activating factor in man.
Thorax. 1989 Feb;44(2):102-7. doi: 10.1136/thx.44.2.102.
7
Paf-induced release of spasmogens from guinea-pig lungs.
Br J Pharmacol. 1989 Jan;96(1):153-62. doi: 10.1111/j.1476-5381.1989.tb11795.x.
8
Effects of inhaled PAF in humans on circulating and bronchoalveolar lavage fluid neutrophils. Relationship to bronchoconstriction and changes in airway responsiveness.
Am Rev Respir Dis. 1990 Feb;141(2):386-92. doi: 10.1164/ajrccm/141.2.386.
9
Platelet activating factor does not cause a reproducible increase in bronchial responsiveness in normal man.
Clin Exp Allergy. 1990 Sep;20(5):525-32. doi: 10.1111/j.1365-2222.1990.tb03145.x.
10
Inhaled PAF fails to induce airway hyperresponsiveness to methacholine in normal human subjects.
J Appl Physiol (1985). 1990 Mar;68(3):919-26. doi: 10.1152/jappl.1990.68.3.919.
Zotero 插件